Wave Life Sciences said today its alpha-1 antitrypsin deficiency (AATD) candidate WVE-006 succeeded in the first-ever clinical demonstration of RNA editing in humans by achieving positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results